| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.19 | 0.3 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |